Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

NCT02294461 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02294461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02294461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2014
Completion date
July 17, 2024
Enrollment
395 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

progressive metastatic prostate cancer